RxDoctor Payments Data

Thomas Heacock, MD

Pulmonary Disease · Fort Collins, CONPI 1215228473

Payments from drug & device makers

$186in general payments, 2019–2025

Across 8 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$46
  • Lilly USA, LLC$31
  • Aerin Medical Inc.$28
  • AstraZeneca$26
  • Regeneron Healthcare Solutions, Inc.$20
  • GSK$18
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$186 in reported general payments places this provider in the 20th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$92,052
Medicare patients
399
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol46$38,743
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$32,448
Spiriva RespimatTiotropium Bromide33$26,460
Spiriva HandihalerTiotropium Bromide21$24,182
Incruse ElliptaUmeclidinium Bromide45$19,504
SymbicortBudesonide/Formoterol Fumarate51$16,887
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$16,060
Advair HfaFluticasone Propion/Salmeterol28$13,804
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$11,892
Tudorza PressairAclidinium Bromide12$5,305
DuleraMometasone/Formoterol11$5,097
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$4,166
Wixela InhubFluticasone Propion/Salmeterol23$3,713
Albuterol Sulfate HfaAlbuterol Sulfate172$3,247
Ventolin HfaAlbuterol Sulfate42$2,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$18$90,694124 claims
AstraZenecaSymbicort$26$16,88751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →